Category: Guest content

Intellectual Property Theft on the Rise

Guest content from John Avellanet, managing director and principal of Cerulean Associates: Intellectual Property Theft on the Rise By John Avellanet, Managing Director and Principal of Cerulean Associates LLC Reprinted with permission from SMARTERCOMPLIANCE™ 2(9): p 1-2 (September 2008) Nine out of ten companies do not have appropriate policies and controls in place to stop […]


Commercializing biotechnology in China

I recently had the opportunity to conduct a brief interview with Mireille Gingras, Ph.D. President and CEO of HUYA Bioscience on doing business with and in China: Tell me about HUYA and what makes the company unique? HUYA Bioscience International has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S. and […]


Contract research helps keep drug pipeline flowing

Guest content from Turner Investment Partners‘ Heather Flick McMeekin, Frank Sustersic, Vijay Shankaran, and Theresa Hoang: Contract research helps keep drug pipeline flowing Imagine a new-product development process that typically lasts 10 to 15 years, has only a one in 5,000 chance of succeeding, and costs at least $800 million. That’s the daunting reality that […]


Background: The Clinical and Translational Science Awards Consortium (CTSA program)

Guest content from Christopher Starr: After years of confusion and neglect, translational research is now becoming institutionalized. Citing the barriers between the lab and clinic, along with the difficulties and complexities of conducting clinical research, the NIH set up a major program to advance clinical and translational research. The Clinical and Translational Science Awards consortium, […]


Why the market does not like Flurizan

Guest content from Nicolaj H. Nielsen, managing director of Biostrat. A case-study on the recent licensing-deal between Myriad and Lundbeck: Information asymmetry, calculated bets and royalties in the biotech industry. The share-price of Lundbeck has fallen with approximately 10 %, since the Danish pharmaceutical company announced an inlicensing deal with the US biotech company Myriad […]


Six Pitfalls to Avoid in Supplier Management

Guest content from John Avellanet, managing director and principal of Cerulean Associates: Managing suppliers is fraught with challenges. Rare is the executive who has not made a mistake. In this article, I look at some of the most common mistakes—most of which I’ve made myself—and how to avoid them.


Seeing the Field

Guest content from Sandy Graham, managing partner at Sequoyah Associates: Can you “see the field” of opportunity? Have your clearly defined your plan to achieve your entrepreneurial dreams? Have you mapped out the strategic direction to attain your plan? Have you envisioned your market and know how to position your business to acquire it? Do […]


Generic Biologics: How to Compete

Guest content from John Avellanet, managing director and principal of Cerulean Associates: Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete. Science Succumbs to Dollars The financial pull on reimbursement organizations and the constituent push on […]


FDA Enforcement Trends: 2007-2008

Guest content from John Avellanet, managing director of Cerulean Associates: The US Food and Drug Administration (FDA) intends to increase regulatory enforcement, extending the recent trend of laboratory and clinical site inspections to unapproved drugs and reformulations. How can you avoid compliance trouble? At the Food and Drug Law Institute’s 5th Annual Enforcement and Litigation […]


Expanding the bandwidth of life science investments: Increasing investment viability

Guest content Contributed by Jayme Norrie, Chief Strategic Officer, Incite World From what we have experienced, angel investors are shoring up the gap in new innovations coming forward. However, they seem to be more naive than VC’s in terms of due diligence prior to investing. Scientists from the company march in with charts and scientific […]